Cassava Sciences awards CEO Barry $355K bonus tied to simufilam TSC epilepsy exploration

FILANA THERAPEUTICS, INC.

Board approved cash bonuses for 2025: CEO Richard Barry $355,000, CFO Eric Schoen $215,000.
Performance measures include exploring simufilam for Tuberous Sclerosis Complex-related epilepsy.
Other goals: building TSC expertise team and budgeting/expense management.
Bonuses reflect contributions in advancing new potential indication for simufilam beyond Alzheimer's.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.